Mission Statement, Vision, & Core Values (2026) of Shenzhen Salubris Pharmaceuticals Co., Ltd.

Founded in 1998 and listed on the Shenzhen Stock Exchange in 2009 (stock code: 002294), Shenzhen Salubris Pharmaceuticals Co., Ltd. is an innovation-driven firm headquartered in Shenzhen that integrates R&D, production and sales to tackle unmet needs in chronic diseases-most notably cardiovascular and cerebrovascular diseases, diabetes, cancer, osteoporosis, and chronic kidney disease-while operating R&D centers in China and the United States and supplying medicines across Europe, Asia, Africa, North America, and South America, guided by core values of Integrity, Collaboration, Excellence, Innovation, and Patient-Centricity and a mission to improve lives through accessible, high-quality pharmaceuticals and sustained global innovation.

Shenzhen Salubris Pharmaceuticals Co., Ltd. (002294.SZ) - Intro

• Mission: Provide outstanding pharmaceutical products for human health and scientifically improve patients' quality of life.
• Vision: Become a globally respected biopharmaceutical company delivering differentiated, high-quality therapies that transform standards of care.
• Core values: Integrity, Collaboration, Excellence, Innovation, Patient-Centricity.

• Integrated value chain: discovery, preclinical, clinical development, GMP manufacturing, and national / international commercialization.
• Global R&D network: multiple centers in China and the United States to connect global innovative resources, study pathogenesis, and accelerate development of innovative drugs.
• Therapeutic focus: chronic cardiovascular & cerebrovascular conditions, diabetes, oncology, osteoporosis, chronic kidney disease - with both innovative molecules and established therapeutics in-market.

• End-to-end capability: discovery biology, translational research, multi-regional clinical trials, and manufacturing scale-up.
• Pipeline priorities: innovative candidates for cardiovascular/cerebrovascular disease, targeted oncology assets, diabetes and renal-disease therapeutics.
• Global collaboration: in-house teams plus strategic partnerships to access external innovation and accelerate first-in-class / best-in-class programs.

• Product portfolio: mix of innovative drugs and established treatments to provide comprehensive therapy options across core therapeutic areas.
• Access and quality: adherence to GMP and regulatory standards to ensure product safety, efficacy and broad patient access.
• Health outcomes: initiatives aimed at chronic disease management to reduce morbidity, hospitalization and long-term healthcare burden.

• Governance: publicly listed governance framework with board oversight, risk management and compliance.
• ESG priorities: patient safety, environmental management in manufacturing, responsible clinical development and community health engagement.

Shenzhen Salubris Pharmaceuticals Co., Ltd. (002294.SZ) Overview

Shenzhen Salubris Pharmaceuticals Co., Ltd. (002294.SZ) positions its corporate purpose around the improvement of patient outcomes through high-quality medicines, broad access, and sustained innovation. The company's stated mission-improving people's lives with exceptional medicines and 'innovation in healthcare for a healthier world'-guides R&D prioritization, market expansion, and social responsibility efforts.

• Core mission: Improve lives with exceptional medicines and drive 'innovation in healthcare for a healthier world.'
• Patient-centered approach: product development and commercialization aligned to clinical needs in hypoglycemia, oncology, orthopaedics, nephropathy, and anti-infection.
• Access and reach: products distributed across multiple countries and regions in Europe, Asia, Africa, North America, and South America to benefit global patient populations.
• Corporate social responsibility: initiatives to ensure affordable medication access and participation in global health programs.

Operational and financial indicators underline how the mission translates into measurable activity:

• Innovation focus areas:
  • Hypoglycemia and metabolic disorders - priority pipelines and marketed therapies.
  • Oncology - targeted therapies and supportive care.
  • Orthopaedics - treatments addressing degenerative and traumatic conditions.
  • Nephropathy - therapies for chronic kidney disease and complications.
  • Anti-infection - antibiotics and anti-infective agents for hospital and community use.
• Access & distribution strategy:
  • Regional partnerships and local registration strategies to expand availability.
  • Tiered pricing and patient assistance programs to improve affordability in lower-income markets.
• Corporate social responsibility highlights:
  • Participation in public health initiatives and donations during health emergencies.
  • Programs to improve medication affordability and supply security in underserved regions.

For investors and stakeholders seeking deeper context on ownership, trading patterns, and strategic positioning, see: Exploring Shenzhen Salubris Pharmaceuticals Co., Ltd. Investor Profile: Who's Buying and Why?

Shenzhen Salubris Pharmaceuticals Co., Ltd. (002294.SZ) - Mission Statement

• Deliver breakthrough medicines and improved clinical outcomes through sustained investment in research and development.
• Expand international footprint to diversify revenue and bring Chinese innovation to global markets.
• Prioritize patient experience and access with targeted support programs and adherence initiatives.
• Operate with environmental responsibility and transparent governance to ensure long-term societal value.
• Foster partnerships across clinicians, regulators, payers, and patient organizations to accelerate adoption and access.

• Innovation-first R&D: Scaling pipeline depth and quality via biologics, specialty small molecules, and lifecycle management of core products.
• Global expansion: Entering prioritized international markets to increase non-domestic revenue share and reduce concentration risk.
• Patient-centricity: Building comprehensive patient support, adherence programs, and digital health interventions to improve outcomes.
• Sustainability & responsibility: Committing to energy efficiency, emissions reductions, and social programs aligned with ESG benchmarks.
• Collaborative ecosystems: Deepening ties with academic research, CROs, hospitals, and regulators to accelerate development and market access.

• Pipeline breadth: Salubris has been accelerating late-stage programs in cardiovascular, oncology-supportive therapies, and biologics-allocating a rising share of capital to biologics and CMC upgrades.
• Investment cadence: R&D expenditures grew roughly in line with revenue growth (R&D CAGR ~15% 2021-2023), signaling a strategic tilt toward innovation over pure volume growth.
• Collaborative research: Increasing partnerships with universities and CROs to shorten timelines and improve access to global trial sites.

• Target markets: Southeast Asia, select MENA countries, and tiered entry into Europe through licensing and local partnerships.
• Commercial model: Hybrid direct-sales in core overseas markets plus licensing/partner models to accelerate market access and regulatory approvals.
• International revenue goal: Management publicly targets doubling overseas revenue share within a 3-5 year horizon from the latest base (~8% to ~16%+ by 2027).

• Patient support expansion: Grew programs from 6 to ~12 within two years, covering medication assistance, adherence reminders, and nurse-led teleconsultations.
• Adherence & outcomes: Pilot programs report adherence improvements of 12-20% and reduced hospital readmissions for chronic therapy cohorts.
• Digital health: Investment in mobile platforms and remote monitoring to scale patient engagement and real-world evidence generation.

• ESG commitments: Emissions intensity reduction target (interim and mid-term milestones), waste management programs in manufacturing, and governance disclosures aligned with major frameworks.
• Community programs: Expanded patient assistance in underserved regions and targeted funding for public health initiatives.
• Board & compliance: Strengthened compliance functions to meet increasingly complex global regulatory requirements as international presence grows.

Shenzhen Salubris Pharmaceuticals Co., Ltd. (002294.SZ) - Vision Statement

Shenzhen Salubris Pharmaceuticals Co., Ltd. (002294.SZ) envisions becoming a globally respected biopharmaceutical leader that sustainably improves patient health through science-driven innovation, uncompromising integrity, and a persistent commitment to delivering value to patients, healthcare partners, and shareholders.

Mission

To scientifically improve quality of life and maintain patient health by providing outstanding pharmaceutical products and services that respond to the real needs of patients and the healthcare community.

Core Values

• Integrity - transparent, ethical conduct across R&D, manufacturing and commercialization.
• Patient-Centricity - prioritizing patient outcomes in product design, access and support.
• Innovation - continuous investment in R&D to develop next-generation therapies and improve existing treatments.
• Collaboration - cross-functional and cross-sector partnerships to accelerate development and access.
• Excellence - operational rigor and quality in manufacturing, regulatory compliance and clinical evidence.
• Responsibility & Inclusiveness - corporate citizenship, safety, and equitable access to healthcare.
• Keeping Promises - honoring commitments to patients, clinicians, employees and investors as a source of trust and long-term happiness.

How These Values Translate into Action

• Patient needs drive the product roadmap: clinical programs prioritized by unmet medical need and real-world impact.
• R&D-led growth model: sustained reinvestment of revenue into drug discovery, clinical development and biomanufacturing capacity.
• Cross-disciplinary collaboration with hospitals, CROs, and academic partners to shorten development timelines and broaden clinical evidence.
• Quality-first manufacturing and supply chain governance to ensure consistent access and regulatory compliance domestically and abroad.

Key Operational and Financial Metrics (Selected)

Strategic Priorities Aligned with Vision & Values

• Scale R&D productivity: increase pipeline depth in cardiovascular, metabolic and immunology/biologics areas.
• Expand access: strengthen distribution and hospital partnerships to improve patient access across China and targeted international markets.
• Quality and compliance: invest in GMP biomanufacturing and pharmacovigilance to meet global regulatory standards.
• Sustainable growth: balance margin improvement with long-term investments in novel therapeutics and digital health initiatives.

For investor-focused context and stakeholder insights, see: Exploring Shenzhen Salubris Pharmaceuticals Co., Ltd. Investor Profile: Who's Buying and Why?